FNBT
ACOR

FineMark National Bank & Trust’s Acorda Therapeutics ACOR Stock Holding History

FineMark National Bank & Trust’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-1
Closed -$3K – 1507
2015
Q3 		$3K Buy
+1
New +$3.88K ﹤0.01% 1199

Other funds holding ACOR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FineMark National Bank & Trust's ACOR Position: Q4 2015 in Review

FineMark National Bank & Trust sold out of Acorda Therapeutics (ACOR) in Q4 2015, closing a stake of 1 share — an estimated $3K sold.

FineMark National Bank & Trust first reported a position in ACOR in Q3 2015 and held it in 1 quarter. The position peaked at $3K in Q3 2015. 186 funds tracked by Wall St. Rank hold ACOR as of Q4 2015.

  • FineMark National Bank & Trust reported no remaining Acorda Therapeutics position as of Q4 2015 after selling out during the quarter.
  • FineMark National Bank & Trust sold 1 Acorda Therapeutics share in Q4 2015, an estimated $3K.
  • FineMark National Bank & Trust first reported a position in Acorda Therapeutics in Q3 2015 and held it in 1 quarter.
  • FineMark National Bank & Trust's Acorda Therapeutics position peaked at $3K in Q3 2015.
  • 186 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q4 2015.

Based on FineMark National Bank & Trust's 13F filing for Q4 2015, filed 9 Feb 2016.